Moreover, CXCR4, one of the receptor of CXCL12, is a poor prognosis factor in breast cancer patients, independently of ER status, and its high expression has been shown to promote estrogen-independent tumor growth in vivo [32]. Here, CXCL12 is linked to neoplasm.